Literature DB >> 29536947

Biofabrication of injectable fibrin microtissues for minimally-invasive therapies: application of surfactants.

Ramkumar T Annamalai, Tapan Naik, Haley Prout, Andrew J Putnam, Jan P Stegemann.   

Abstract

Microtissues created from the protein fibrin and containing embedded cells can be used in modular tissue engineering approaches to create larger, hierarchical and complex tissue structures. In this paper we demonstrate an emulsification-based method for the production of such fibrin microtissues containing fibroblasts (FB) and endothelial cells (EC) and designed to promote tissue vascularization. Surfactants can be beneficial in the microtissue fabrication process to reduce aggregation and to facilitate recovery of microtissues from the emulsion, thereby increasing yield. The nonionic surfactants Pluronic L101® and Tween 20® both increased microtissue yield in a dose-dependent fashion. Cell viability of both human FB and human EC remained high after exposure to low surfactant concentrations but decreased with increasing surfactant concentration. L101 was markedly less cytotoxic than Tween, and therefore was the surfactant of choice in this application. The yield of cell-laden microtissues increased with increasing L101 concentration, though microtissues were slightly larger at low concentrations. The total metabolic activity of cells in retrieved microtissues was bimodal and was highest at an L101 concentration of 0.10% wt/vol. Network formation by EC in microtissues embedded in surrounding 3D fibrin hydrogels was also most extensive in microtissues made using an L101 concentration of 0.10% wt/vol. Minimally-invasive delivery of microtissue populations was demonstrated by injection through a standard 18 G needle, and the ability to form robust endothelial networks was maintained in injected microtissue populations. Taken together, these data demonstrate a facile emulsification-based method to create modular, cell-laden hydrogel microtissues that can be delivered by injection to promote tissue regeneration. Appropriate selection of the type and concentration of surfactant used in the process can be used to maximize viability and specialized function of the embedded cells. Such biomaterial-based microtissues may have broad applicability in cell-based therapies and tissue engineering.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29536947      PMCID: PMC5938738          DOI: 10.1088/1748-605X/aab66f

Source DB:  PubMed          Journal:  Biomed Mater        ISSN: 1748-6041            Impact factor:   3.715


  32 in total

1.  Biophysical properties of dermal building-blocks affects extra cellular matrix assembly in 3D endogenous macrotissue.

Authors:  F Urciuolo; A Garziano; G Imparato; V Panzetta; S Fusco; C Casale; P A Netti
Journal:  Biofabrication       Date:  2016-01-29       Impact factor: 9.954

Review 2.  Emerging medical devices for minimally invasive cell therapy.

Authors:  Eoin D O'Cearbhaill; Kelvin S Ng; Jeffrey M Karp
Journal:  Mayo Clin Proc       Date:  2014-02       Impact factor: 7.616

3.  Directed Assembly and Development of Material-Free Tissues with Complex Architectures.

Authors:  Erik Vrij; Jeroen Rouwkema; Vanessa LaPointe; Clemens van Blitterswijk; Roman Truckenmüller; Nicolas Rivron
Journal:  Adv Mater       Date:  2016-03-22       Impact factor: 30.849

Review 4.  The molecular origins of the mechanical properties of fibrin.

Authors:  Michael R Falvo; Oleg V Gorkun; Susan T Lord
Journal:  Biophys Chem       Date:  2010-11       Impact factor: 2.352

5.  A new bioerodible polymer insert for the controlled release of metronidazole.

Authors:  K A Gates; H Grad; P Birek; P I Lee
Journal:  Pharm Res       Date:  1994-11       Impact factor: 4.200

6.  Mechanism of pluronic effect on P-glycoprotein efflux system in blood-brain barrier: contributions of energy depletion and membrane fluidization.

Authors:  E V Batrakova; S Li; S V Vinogradov; V Y Alakhov; D W Miller; A V Kabanov
Journal:  J Pharmacol Exp Ther       Date:  2001-11       Impact factor: 4.030

7.  Fibrin-loaded porous poly(ethylene glycol) hydrogels as scaffold materials for vascularized tissue formation.

Authors:  Bin Jiang; Thomas M Waller; Jeffery C Larson; Alyssa A Appel; Eric M Brey
Journal:  Tissue Eng Part A       Date:  2012-09-24       Impact factor: 3.845

8.  Polysorbate 20 Degradation in Biopharmaceutical Formulations: Quantification of Free Fatty Acids, Characterization of Particulates, and Insights into the Degradation Mechanism.

Authors:  Anthony Tomlinson; Barthélemy Demeule; Baiwei Lin; Sandeep Yadav
Journal:  Mol Pharm       Date:  2015-10-13       Impact factor: 4.939

9.  Spatiotemporal regulation of chondrogenic differentiation with controlled delivery of transforming growth factor-β1 from gelatin microspheres in mesenchymal stem cell aggregates.

Authors:  Loran D Solorio; Chirag D Dhami; Phuong N Dang; Eran L Vieregge; Eben Alsberg
Journal:  Stem Cells Transl Med       Date:  2012-07-27       Impact factor: 6.940

10.  Collagen Type II enhances chondrogenic differentiation in agarose-based modular microtissues.

Authors:  Ramkumar Tiruvannamalai Annamalai; David R Mertz; Ethan L H Daley; Jan P Stegemann
Journal:  Cytotherapy       Date:  2016-02       Impact factor: 5.414

View more
  3 in total

1.  Micropatterning of acoustic droplet vaporization in acoustically-responsive scaffolds using extrusion-based bioprinting.

Authors:  Mitra Aliabouzar; Adam W Y Ley; Sabine Meurs; Andrew J Putnam; Brendon M Baker; Oliver D Kripfgans; J Brian Fowlkes; Mario L Fabiilli
Journal:  Bioprinting       Date:  2021-12-28

2.  Fabrication and characterization of osteogenic function of progenitor cell-laden gelatin microcarriers.

Authors:  Chukwuma E Nweke; Jan P Stegemann
Journal:  J Biomed Mater Res B Appl Biomater       Date:  2021-12-17       Impact factor: 3.368

3.  Bioresponsive microspheres for on-demand delivery of anti-inflammatory cytokines for articular cartilage repair.

Authors:  Eunjae Park; Melanie L Hart; Bernd Rolauffs; Jan P Stegemann; Ramkumar T Annamalai
Journal:  J Biomed Mater Res A       Date:  2019-12-12       Impact factor: 4.396

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.